These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34128831)

  • 1. The tumor microenvironment and immune responses in prostate cancer patients.
    Kwon JTW; Bryant RJ; Parkes EE
    Endocr Relat Cancer; 2021 Jul; 28(8):T95-T107. PubMed ID: 34128831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
    Stultz J; Fong L
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.
    Olson B; Patnaik A
    Urol Oncol; 2019 Aug; 37(8):535-542. PubMed ID: 30503851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
    Wong RL; Yu EY
    Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
    Philippou Y; Sjoberg HT; Murphy E; Alyacoubi S; Jones KI; Gordon-Weeks AN; Phyu S; Parkes EE; Gillies McKenna W; Lamb AD; Gileadi U; Cerundolo V; Scheiblin DA; Lockett SJ; Wink DA; Mills IG; Hamdy FC; Muschel RJ; Bryant RJ
    Br J Cancer; 2020 Sep; 123(7):1089-1100. PubMed ID: 32641865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for prostate cancer: Requirements for a successful regime transfer.
    Jeong SH; Kwak C
    Investig Clin Urol; 2022 Jan; 63(1):3-13. PubMed ID: 34983117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
    Jindal V
    Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling new therapeutic opportunities: cytokines in prostate cancer.
    Chandran E; Meininger L; Karzai F; Madan RA
    Expert Opin Biol Ther; 2022 Oct; 22(10):1233-1243. PubMed ID: 35930001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
    Jansen CS; Prokhnevska N; Kissick HT
    Urol Oncol; 2019 Aug; 37(8):543-555. PubMed ID: 30446449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
    Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
    Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive review of immunotherapies in prostate cancer.
    Maia MC; Hansen AR
    Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer.
    Zhu Y; Duong L; Lu X; Lu X
    Asian J Androl; 2023; 25(2):171-178. PubMed ID: 36367020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
    Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR
    Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer immunotherapy: where are we and where are we going?
    De Velasco MA; Uemura H
    Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.